# A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

> clinical trial · VERIFIED · 2026-07-16

Status: NOT_YET_RECRUITING · Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Condition: Platinum-resistant Ovarian Cancer

- Company: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07708753

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.